Pegunigalsidase alfa receives priority review designation in the US for treatment of Fabry disease

Priority review of this pegylated alpha-galactosidase replacement therapy was granted on the basis of completed phase II trial, and interim results from the phase III BRIDGE study. A marketing authorisation application has not yet been submitted for use in Europe.


Biospace Inc.